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Increased Risk of Mortality in Patients With
Low-Flow Low-Gradient Aortic Stenosis
and Reduced Ejection Fraction
Results of the Multicenter TOPAS Study
(True or Pseudo-Severe Aortic Stenosis)Abdellaziz Dahou, MD, MSC,* Julien Magne, PHD,yz Marie-Annick Clavel, DVM, PHD,* Romain Capoulade, PHD,*
Philipp Emanuel Bartko, MD, PHD,x Jutta Bergler-Klein, MD,x Mario Sénéchal, MD,* Gerald Mundigler, MD,x
Ian Burwash, MD,k Henrique B. Ribeiro, MD,* Kim O’Connor, MD,* Patrick Mathieu, MD,*
Helmut Baumgartner, MD,{ Jean G. Dumesnil, MD,* Raphael Rosenhek, MD,x Eric Larose, MD,*
Josep Rodés-Cabau, MD,* Philippe Pibarot, DVM, PHD*ABSTRACTOBJECTIVES This study sought to examine the impact of tricuspid regurgitation (TR) on mortality in patients with
low-ﬂow, low-gradient (LF-LG) aortic stenosis (AS) and reduced left ventricular ejection fraction (LVEF).
BACKGROUND TR is often observed in patientswith LF-LG AS and low LVEF, but its impact on prognosis remains unknown.
METHODS A total of 211 patients (73  10 years of age; 77% men) with LF-LG AS (mean gradient <40 mm Hg and
indexed aortic valve area [AVA] #0.6 cm2/m2) and reduced LVEF (#40%) were prospectively enrolled in the TOPAS
(True or Pseudo-Severe Aortic Stenosis) study and 125 (59%) of them underwent aortic valve replacement (AVR) within
3 months following inclusion. The severity of AS was assessed by the projected AVA (AVAproj) at normal ﬂow rate
(250 ml/s), as previously described and validated. The severity of TR was graded according to current guidelines.
RESULTS Among the 211 patients included in the study, 22 (10%) had no TR, 113 (54%) had mild (grade 1), 50 (24%)
mild-to-moderate (grade 2), and 26 (12%) moderate-to-severe (grade 3) or severe (grade 4) TR. During a mean follow-up
of 2.4  2.2 years, 104 patients (49%) died. Univariable analysis showed that TR$2 was associated with increased risk of
all-cause mortality (hazard ratio [HR]: 1.82, 95% conﬁdence interval [CI]: 1.22 to 2.71; p ¼ 0.004) and cardiovascular
mortality (HR: 1.85, 95% CI: 1.20 to 2.83; p ¼ 0.005). After adjustment for age, sex, coronary artery disease, AVAproj,
LVEF, stroke volume index, right ventricular dysfunction, mitral regurgitation, and type of treatment (AVR vs. conser-
vative), the presence of TR $2 was an independent predictor of all-cause mortality (HR: 1.88, 95% CI: 1.08 to 3.23;
p ¼ 0.02) and cardiovascular mortality (HR: 1.92, 95% CI: 1.05 to 3.51; p ¼ 0.03). Furthermore, in patients undergoing
AVR, TR $3 was an independent predictor of 30-day mortality compared with TR ¼ 0/1 (odds ratio [OR]: 7.24, 95% CI:
1.56 to 38.2; p ¼ 0.01) and TR ¼ 2 (OR: 4.70, 95% CI: 1.00 to 25.90; p ¼ 0.05).
CONCLUSIONS In patients with LF-LG AS and reduced LVEF, TR is independently associated with increased risk of
cumulative all-cause mortality and cardiovascular mortality regardless of the type of treatment. In patients undergoing
AVR, moderate/severe TR is associated with increased 30-day mortality. Further studies are needed to determine
whether TR is a risk marker or a risk factor of mortality and whether concomitant surgical correction of TR at the time
of AVR might improve outcomes for this high-risk population. (J Am Coll Cardiol Intv 2015;8:588–96) © 2015 by the
American College of Cardiology Foundation.
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589AB BR E V I A T I O N S
AND ACRONYM S
AS = aortic stenosis
AVA = aortic valve area
AVAproj = projected aortic
valve area at normal ﬂow rate
AVR = aortic valve
replacement
CI = conﬁdence interval
HR = hazard ratio
LF-LG = low-ﬂow,
low-gradient
LVEF = left ventricular
ejection fractionP atients with low-ﬂow, low-gradient (LF-LG)aortic stenosis (AS) and reduced left ventricu-lar ejection fraction (LVEF) have a poor prog-
nosis with conservative therapy but a high operative
mortality with aortic valve replacement (AVR) (1–7).
Risk stratiﬁcation is essential in these patients to
optimize therapeutic management and outcomes.
Previous studies have reported that multivessel coro-
nary artery disease, mean gradient <20 mm Hg,
absence of LV ﬂow reserve on dobutamine stress
echocardiography, peak stress LVEF <35%, and
more severe stenosis on dobutamine stress echocar-
diography are associated with worse outcomes in pa-
tients with LF-LG AS (2–5,8).SEE PAGE 597
OR = odds ratio
RV = right ventricular
SVI = stroke volume index
tricuspid regurgitationFunctional tricuspid regurgitation (TR) is a com-
mon ﬁnding in patients with left-sided heart valve
diseases (9–15). Several studies have reported an
increased risk of mortality in chronic heart failure
patients having moderate or severe TR (9,14,16,17).
No data exist about the prevalence and prognosis of
TR in patients with LF-LG AS. The objective of this
study was to examine the impact of TR on mortality
in patients with LF-LG AS and low LVEF.
METHODS
STUDY PROTOCOL. For the purpose of this study, we
analyzed the data of patients prospectively recruited
in the TOPAS (True or Pseudo-Severe Aortic Stenosis)
multicenter prospective observational study (7,18).
Between July 24, 2002 and March 1, 2012, 211 patients
with LF-LG AS (mean gradient <40 mm Hg, indexed
aortic valve area [AVA] #0.6 cm2/m2) with re-
duced LVEF (#40%) were recruited in 3 academic
centers (Québec, Ottawa, and Vienna). Patients wereFrom the *Department of Cardiology, Institut Universitaire de Cardiologie et
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regurgitation, greater than mild organic
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CLINICAL DATA. Clinical data included age,
sex, height, weight, body surface area, sys-
tolic and diastolic blood pressure, New York
Heart Association functional class, docu-
mented diagnosis of traditional cardiovascu-
lar risk factors and comorbidities such as
hypertension, diabetes, dyslipidemia, smok-
ing, and chronic obstructive pulmonary dis-
ease, coronary artery disease (history of
myocardial infarction or $50% coronary ar-
tery stenosis on coronary angiography), and
logistic EuroSCORE (European System for
Cardiac Operative Risk Evaluation). Medi-
cation was recorded at the time of
echocardiography.
DOPPLER ECHOCARDIOGRAPHY. At baseline, all
patients underwent comprehensive echocardiogra-
phy at rest and during dobutamine stress echocardi-
ography as previously described (18). LVEF was
measured by the biplane Simpson method. Stroke
volume was measured in the LV outﬂow tract and
indexed for body surface area. AVA was measured
using the continuity equation. AS severity was
assessed using the projected AVA at a normal trans-
valvular ﬂow rate (AVAproj) (18,19).
The severity of TR was assessed using an integrated
approach and graded as none (0), mild (grade 1), mild-
to-moderate (grade 2), moderate-to-severe (grade 3),
and severe (grade 4) according to current guidelines
(20–22). Tricuspid annulus diameter was measured
at end diastole from a right ventricle–focused apical
4-chamber view as recommended (23,24). Systolic
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590pulmonary arterial pressure was calculated by add-
ing the peak TR systolic gradient and the estimated
central venous pressure. Right ventricular (RV)
function was assessed by an integrative approach
and classiﬁed as normal or reduced (25).
STATISTICAL ANALYSIS. Results are expressed as
mean  SD or percents unless otherwise speciﬁed.
Differences between patients in different groups were
compared with the use of 1-way analysis of variance
and Tukey test for continuous variables and the chi-
square test for categorical variables. Kaplan-Meier
curves and log-rank test of the time-to-event data
were used to assess the effect of TR on mortality. The
effect of the clinical and Doppler-echocardiographic
variables on survival was assessed with the use of
Cox proportional hazard regression models for
cumulative all-cause mortality and with backward
stepwise logistic regression analysis for 30-day mor-
tality in the subset of patients undergoing AVR. The
proportional hazards assumption was checked with
the use of Schoenfeld residuals. All the variables with
a p value of <0.10 in univariable analysis and those
with clinical relevance regardless of their level of
signiﬁcance (i.e., age, sex, systolic pulmonary arterial
pressure and type of treatment [AVR vs. conserva-
tive]) were incorporated in the multivariable models.
Further adjustment for classical echocardiographic
parameters of LV systolic function (i.e., LVEF and
stroke volume index [SVI]) and RV systolic function
was performed. A p value <0.05 was considered
statistically signiﬁcant.
RESULTS
PATIENT CHARACTERISTICS. Patient characteristics
are shown in Table 1. Among the 211 patients
included in this study (mean age: 73  10 years;
77%, n ¼ 163 male), 108 (51%) were classiﬁed as
New York Heart Association functional class III or
greater. One hundred and twenty-ﬁve patients
(59%) underwent AVR within 3 months of enroll-
ment and the remaining patients (n ¼ 86, 41%) were
treated conservatively. Among patients undergoing
AVR, 99 (79%) were treated surgically (55 with
concomitant coronary artery bypass graft surgery
and 3 with concomitant tricuspid valve annulo-
plasty) and 26 (21%) were treated by transcatheter
procedure.
There were 22 patients (10%) with no TR, 113 (54%)
with grade 1, 50 (24%) with grade 2, and 26 (12%) with
grade 3 or 4 (3/4) TR. Patients with TR ¼ 3/4 had
similar baseline demographics and prevalence of
cardiovascular risk factors as did those with TR ¼ 2 or
those with TR ¼ 0/1 (Table 1), except for diabetes,which was more prevalent (p ¼ 0.01) in patients with
TR ¼ 3/4. Regarding Doppler echocardiographic data,
AVA was signiﬁcantly smaller in patients with TR but
mean gradient and projected AVA were similar
among groups (Table 1). Patients with TR had signif-
icantly lower LVEF (p ¼ 0.02), lower SVI (p < 0.0001),
higher prevalence of secondary mitral regurgitation
(p ¼ 0.001), and larger tricuspid annulus diameter
(p < 0.0001). Patients with TR ¼ 3/4 had higher
prevalence of reduced RV function than did those
with TR ¼ 0/1 and those with TR ¼ 2 (Table 1).
IMPACT OF TRICUSPID REGURGITATION ON MORTALITY.
During a mean follow-up of 2.4  2.2 years, 104
patients (49%) died (87 deaths [84%] were from
cardiovascular causes) resulting in 2- and 4-year
survival rates of 65  3% and 48  4%, respec-
tively. Patients with TR $2 had signiﬁcantly lower
2- and 4-year survival rates (Figure 1A) than did
those with TR ¼ 0/1 (50  6% vs. 73  4% and 30  6%
vs. 58  5%; log-rank: p ¼ 0.003, respectively).
The patients with TR ¼ 1 had similar survival as those
with no TR (4-year survival: 55  10% vs. 58  6%;
p ¼ 0.32).
Univariable analysis showed that TR $2 was asso-
ciated with increased risk of all-cause mortality
(hazard ratio [HR]: 1.82, 95% conﬁdence interval [CI]:
1.22 to 2.71; p ¼ 0.004) as well as of cardiovascular
mortality (HR: 1.85, 95% CI: 1.20 to 2.83; p ¼ 0.005).
After adjustment for type of treatment (AVR vs.
conservative), TR $2 remained associated with in-
creased risk of all-cause mortality (HR: 1.99, 95% CI:
1.32 to 2.98; p ¼ 0.001) (Table 2) and cardiovascular
mortality (HR: 2.03, 95% CI: 1.31 to 3.12; p ¼ 0.001).
In multivariable Cox proportional hazard model
adjusted for age, sex, coronary artery disease, dia-
betes, AVAproj, LVEF, SVI, systolic pulmonary arterial
pressure, mild or greater secondary mitral regurgita-
tion and type of treatment, the presence of TR $2
was an independent predictor of all-cause mortality
(HR: 1.91, 95% CI: 1.13 to 3.26; p ¼ 0.01) (Table 2) and
cardiovascular mortality (HR: 1.92, 95% CI: 1.05
to 3.51; p ¼ 0.03). There was a graded relationship
between TR severity and the tricuspid annulus
diameter (Figure 2). However, the independent
association between TR and all-cause mortality per-
sisted after further adjustment for tricuspid annulus
diameter (HR: 1.91, 95% CI: 1.04 to 3.53; p ¼ 0.03)
or RV dysfunction (HR: 1.88, 95% CI: 1.08 to 3.23;
p ¼ 0.02).
Patients with TR ¼ 3/4 had signiﬁcant lower 2-year
survival (Figure 1B) than did those with TR ¼ 2
and those with TR ¼ 0/1 (41  10% vs. 56  8% and
73  4%; p ¼ 0.005, respectively). Additional analyses
TABLE 1 Baseline Clinical and Doppler Echocardiographic Characteristics of the Study Population
Whole Cohort
(N ¼ 211)
Grade 0/1 TR
(n ¼ 135; 64%)
Grade 2 TR
(n ¼ 50; 24%)
Grade 3/4 TR
(n ¼ 26; 12%) p Value
Demographics and physical exam
Age, yrs 73.0  10.0 71.6  10.0 74.7  10.0 72.3  9.6 0.2
Male 163 (77) 107 (79) 36 (72) 20 (77) 0.6
Body surface area, m2 1.84  0.21 1.86  0.21 1.82  0.23 1.82  0.18 0.8
Systolic blood pressure, mm Hg 120  18 122  18 118  17 117  18 0.2
Diastolic blood pressure, mm Hg 72  10 73  10 70  11 73  9 0.4
NYHA functional class $III 108 (51) 67 (50) 28 (56) 13 (50) 0.8
Risk factors and concomitant diseases
Hypertension 136 (64) 88 (65) 31 (62) 17 (65) 0.9
Diabetes 74 (35) 43 (32) 15 (30) 16 (62)* 0.01
Dyslipidemia 148 (70) 92 (68) 36 (72) 20 (77) 0.7
Smoking 125 (59) 74 (55) 33 (66) 18 (69) 0.3
Coronary artery disease 136 (64) 88 (65) 37 (74) 19 (73) 0.7
Coronary artery bypass graft 74 (35) 37 (27) 15 (30) 7 (27) 0.9
Previous myocardial infarction 110 (52) 69 (51) 25 (50) 16 (62) 0.6
Chronic obstructive pulmonary disease 60 (28) 35 (26) 15 (30) 10 (38) 0.4
Logistic EuroSCORE, % 23.5  18.5 21.9  18.3 25.4  20.3 27.3  16.7 0.5
Medication
Beta-blockers 131 (62) 87 (64) 28 (56) 16 (62) 0.8
Diuretic agents 148 (70) 87 (64)† 39 (78) 22 (85) 0.03
ACEI/ARB 121 (57) 81 (60) 27 (54) 13 (50) 0.5
Statins 128 (60) 79 (58) 31 (62) 18 (69) 0.5
Doppler echocardiographic data
LV end-diastolic diameter, mm 58  10 59  11 58  8 57  8 0.5
LV end-systolic diameter, mm 48  10 48  11 48  9 48  9 0.9
Left atrial diameter, mm 45  9 46  10 44  9 46  5 0.6
LV stroke volume, ml 57  17 61  18† 52  13 45  13 <0.0001
LV stroke volume index, ml/m2 31  9 33  9† 29  6 24  6 <0.0001
LV ejection fraction, % 29  9 29  9 29  6 24  8* 0.02
Mitral regurgitation > mild 23 (11) 7 (5)† 9 (18) 7 (27) 0.001
Tricuspid annulus diameter, mm 41  7 39  6 42  8 48  6* <0.0001
Systolic pulmonary arterial pressure, mm Hg 46  13 44  12 47  15 52  12 0.12
Reduced RV systolic function 108 (51) 61 (45) 27 (54) 20 (77)* 0.02
Mean transvalvular gradient, mm Hg 24  9 24  8 25  9 24  7 0.5
Aortic valve area, cm2 0.84  0.24 0.88  0.22† 0.77  0.23 0.73  0.26 0.0006
Projected aortic valve area, cm2 1.02  0.21 1.04  0.20 0.99  0.20 1.03  0.30 0.5
Values are mean  SD or n (%). *p < 0.05 for grade 3/4 versus 0/1 and 2. †p < 0.05 for grade 0/1 versus 2 and 3/4.
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation; LV ¼ left
ventricular; NYHA ¼ New York Heart Association; RV ¼ right ventricular; TR ¼ tricuspid regurgitation.
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591according to the type of treatment showed that TR
severity was associated with increased risk of mor-
tality in both patients treated with AVR (p ¼ 0.02)
(Figure 1C) and those treated conservatively (p ¼ 0.05)
(Figure 1D). Univariable Cox regression analysis
showed that patients with TR ¼ 2 (HR: 1.62, 95% CI:
1.02 to 2.54; p ¼ 0.04) and those with TR ¼ 3/4 (HR:
2.30, 95% CI: 1.27 to 3.93; p ¼ 0.007) (Table 3) had
increased risk of mortality than did those with TR ¼
0/1. After adjustment for type of treatment (AVR vs.
conservative), presence of TR ¼ 2 (HR: 1.76, 95% CI:
1.10 to 2.77; p ¼ 0.02) and TR ¼ 3/4 (HR: 2.34, 95% CI:1.27 to 4.07; p ¼ 0.008) (Table 3) were signiﬁcantly
associated with increased risk of all-cause mortality.
After further adjustment for other risk factors, TR ¼ 2
(HR: 2.19, 95% CI: 1.00 to 4.77; p ¼ 0.05) and TR ¼ 3/4
(HR: 2.68, 95% CI: 1.08 to 6.32; p ¼ 0.03) (Table 3)
remained signiﬁcantly associated with increased risk
of all-cause mortality.
There was no signiﬁcant interaction between the
center where the patient was recruited (i.e., Québec,
Ottawa, or Vienna) and TR with respect to impact
on mortality. Furthermore, in hierarchical multivari-
able analysis including the center, TR remained
FIGURE 1 Impact of TR on All-Cause Mortality for the Whole Cohort
The survival rates for the whole cohort (N ¼ 211) according to the grade of tricuspid regurgitation (TR) (grade 0/1 vs. grade $2 [A]; grade 0/1
vs. grade 2 vs. grade 3/4 [B]) are shown. (C) The survival rates are shown for the patients treated with aortic valve replacement according to
the severity of TR. (D) The survival rates are shown for the patients treated conservatively according to TR severity. *Hazard ratio (HR) and
p value for TR ¼ 2 versus TR ¼ 0/1; §HR and p value for TR ¼ 3/4 versus TR ¼ 0/1. The numbers at the bottom of the graph represent the
number of patients at risk at each follow-up year.
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592signiﬁcantly associated with mortality (TR $2: HR:
2.53, 95% CI: 1.41 to 4.56; p ¼ 0.002).
IMPACT OF TRICUSPID REGURGITATION ON 30-DAY
MORTALITY IN PATIENTS TREATED BY AVR. Among
patients who underwent AVR (n ¼ 125), there
were 16 patients with TR ¼ 3/4 and 37 with TR ¼ 2.
Fifteen patients died following AVR resulting in
30-day mortality of 12%. Six deaths (37.5%) occurred
in the group of patients with TR ¼ 3/4 compared with
4 (10.8%) in those with TR ¼ 2, and 5 (6.9%) in those
with TR ¼ 0/1 (p < 0.05) (Figure 3).
Univariable logistic regression analysis showed
that TR ¼ 3/4 was associated with increased risk of
30-day mortality compared with TR ¼ 0/1 (odds ratio[OR]: 8.04, 95% CI: 2.07 to 33.06; p ¼ 0.003) and
TR ¼ 2 (OR: 4.95, 95% CI: 1.19 to 22.06; p ¼ 0.028).
However, TR ¼ 2 was not associated with increased
risk of 30-day mortality (OR: 1.62, 95% CI: 0.38 to
6.53; p ¼ 0.49). In multivariable logistic regression,
TR ¼ 3/4 was an independent predictor of 30-day
mortality compared with TR ¼ 0/1 (OR: 7.24, 95% CI:
1.56 to 38.2; p ¼ 0.01) and TR ¼ 2 (OR: 4.70, 95% CI:
1.00 to 25.90; p ¼ 0.05).
AVR was nonetheless associated with reduced
risk of mortality in univariable analysis (HR: 0.62,
95% CI: 0.41 to 0.91; p ¼ 0.015) as well as in
multivariable analysis after adjustment for clinical
risk factors and echocardiographic parameters of
AS severity, LV dysfunction, RV dysfunction, and
FIGURE 2 Relationship Between Tricuspid Annulus Diameter
and TR Severity
The graph shows the relationship between tricuspid annulus
diameter and tricuspid regurgitation (TR) severity.
TABLE 2 Impact of TR (Grade $2) on All-Cause Mortality
HR 95% CI p Value
Unadjusted analysis 1.82 1.22–2.71 0.004
Analysis adjusted for
Type of treatment
(AVR vs. conservative)
1.99 1.32–2.98 0.001
Type of treatment, age, sex,
CAD, diabetes, AVAproj,
LVEF, SVI, SPAP, and MR
1.91 1.13–3.26 0.01
Type of treatment, age, sex,
CAD, diabetes, AVAproj, LVEF, SVI,
SPAP, MR, and RV dysfunction
1.88 1.08–3.23 0.02
AVAproj ¼ projected aortic valve area at normal ﬂow rate; AVR ¼ aortic valve
replacement; CAD ¼ coronary artery disease; CI ¼ conﬁdence interval;
HR ¼ hazard ratio; LVEF ¼ left ventricular ejection fraction; MR ¼ mitral regur-
gitation; SPAP ¼ systolic pulmonary arterial pressure; SVI ¼ stroke volume index;
other abbreviations as in Table 1.
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593TR severity (HR: 0.42, 95% CI: 0.20 to 0.87;
p ¼ 0.019).
DISCUSSION
There are 3 main ﬁndings of the present study: 1) TR
is independently associated with increased risk of
cumulative all-cause mortality and cardiovascularFIGURE 3 Impact of TR on 30-Day Mortality
The graph shows the impact of tricuspid regurgitation (TR) on
perioperative (30-day) mortality in the subset of patients who
underwent aortic valve replacement.mortality in patients with low LVEF, LF-LG AS;
2) there is a graded association between TR severity
and increased risk of mortality; and 3) moderate/
severe TR is independently associated with increased
risk of 30-day mortality following AVR.
TR AND LATE OUTCOMES IN LF-LG AS. In the pre-
sent study, TR was associated with increased risk
of mortality independently of comorbidities, LV
function, AS severity, mitral regurgitation severity,
and type of treatment (AVR vs. conservative).
Furthermore, mortality risk increased with the
severity of TR. These ﬁndings are consistent with
those previously published (16,17) in patients with
chronic heart failure where moderate/severe TR was
associated with increased risk of mortality.
TR can contribute to reduced LV outﬂow (forward
stroke volume), which has been shown to be a strong
predictor of mortality in patients with AS (26,27).
Accordingly, our patients with more severe TR hadTABLE 3 Impact of TR Severity on All-Cause Mortality
TR Grade HR 95% CI p Value
Unadjusted analysis 0/1 Ref. — —
2 1.62 1.02–2.54 0.04
3/4 2.30 1.27–3.93 0.007
Analysis adjusted for
Type of treatment
(AVR vs. conservative)
0/1 Ref. — —
2 1.76 1.10–2.77 0.02
3/4 2.34 1.27–4.07 0.008
Type of treatment, age, sex,
CAD, AVAproj, LVEF, SVI, SPAP,
MR, and RV dysfunction
0/1 Ref. — —
2 2.19 1.00–4.77 0.05
3/4 2.68 1.08–6.32 0.03
This table shows the impact of TR grade 2 or 3/4 versus 0/1 (referent group) on
mortality.
Ref. ¼ referent group; other abbreviations as in Tables 1 and 2.
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594lower SVI. However, even after adjustment for SVI,
TR remained independently associated with reduced
survival.
Previous studies in patients undergoing left-sided
valve surgery have reported that dilation of the tri-
cuspid annulus is a powerful predictor of progressive
TR even in patients with only mild secondary TR (25).
In the present cohort, both patients with grade 2 TR
and those with grades 3/4 TR had signiﬁcant tricuspid
annulus dilation (Figure 2). The association between
the presence/severity of TR and mortality nonethe-
less persisted after adjustment for tricuspid annulus
diameter.
The underlying mechanisms related to the higher
mortality in patients with TR remain unclear. Previ-
ous studies (14,16) have shown that the presence of
TR predicts RV dilation and dysfunction and is asso-
ciated with worse survival. However in the study by
Nath et al. (16), RV dysfunction explained only part of
this association. In the latter study, the investigators
hypothesized that TR may be a more sensitive marker
of RV dysfunction than the visual assessment of RV
systolic performance. In fact, the presence of TR may
mask reduced RV contractility, in a similar way as
mitral regurgitation limits the ability of LVEF to
identify impaired LV contractility. In our study, TR
remained associated with increased risk of mortality
even after further adjustment for the presence of RV
dysfunction.
TR AND 30-DAY MORTALITY IN LF-LG AS. In the
subset of patients treated with AVR, our data showed
that 30-day mortality was markedly higher in patients
with TR than in those without TR. Boldt et al. (28)
showed that in patients with severe AS, pre-
operative RV dysfunction was associated with a
greater occurrence of hemodynamic instability and
greater requirement of post-operative inotropic sup-
port; however, they did not have the statistical power
to analyze mortality. Our results extend these obser-
vations and strongly emphasize the importance of TR
and associated RV dilation (tricuspid annular dila-
tion) and dysfunction in patients with LF-LG AS and
low LVEF.
In the present study, AVR was associated with
improved late survival even after adjustment for
other risk factors including TR. These ﬁndings are
consistent with previous studies suggesting that AVR
is protective in patients with low LVEF, LF-LG AS,
including those with no LV contractile reserve
(2,5,26). Hence, the presence of TR should not pre-
clude consideration of AVR in patients with LF-LG AS.
CLINICAL IMPLICATIONS. The main clinical impli-
cation of this study is that presence and severityof TR should be systematically integrated in the
risk stratiﬁcation process of patients with LF-LG
AS and reduced LVEF. The present study indeed
shows that TR $2 is independently associated with
2-fold increased risk of mortality in these patients.
This information would also lend support to the
consideration of concomitant tricuspid annuloplasty
in the subset of patients undergoing AVR. According
to the 2012 European Society of Cardiology guide-
lines (25), tricuspid valve surgery is indicated (Class I;
Level of Evidence: C) in patients with severe TR
and should be considered (Class IIa; Level of Evi-
dence: C) in patients with moderate primary TR
as well as in patients with mild or moderate sec-
ondary TR and signiﬁcant dilation of the tricuspid
annulus ($40 mm or 21 mm/m2) undergoing left-
sided valve surgery. However, these recommenda-
tions are mainly on the basis of data arising from
a small number of retrospective studies of patients
requiring mitral valve replacement/repair for mitral
stenosis. Hence, further studies are needed to
determine the risk/beneﬁt ratio of a concomitant
tricuspid valve procedure in patients with LF-LG
AS and low LVEF undergoing AVR. It indeed re-
mains unclear whether the correction of a secondary
TR in these patients would translate into better
outcomes.
STUDY LIMITATIONS. The population size, albeit
large for this clinical entity, may have limited our
ability to detect signiﬁcant associations with other
risk factors in the total cohort, as well as in the sub-
group of patients undergoing AVR.
It is possible that, due to the reduced RV function
and low-ﬂow state, the TR severity was under-
estimated in some patients included in this study,
similar to what may occur in patients with secondary
mitral regurgitation. Although RV function was
qualitatively assessed by the cardiologist for each
patient, the quantitative parameters of RV function
(e.g., tricuspid annular plane systolic excursion,
tricuspid annulus systolic velocity) were not system-
atically measured in this study and were available
only in a small subset of patients. Further studies are
needed to assess the respective impact of RV function
and TR in patients with LF-LG AS.CONCLUSIONS
In patients with LF-LG AS and reduced LVEF, TR is
independently associated with increased risk of
mortality. Increasing TR severity is associated with a
greater risk of mortality. Furthermore, moderate/
severe TR is independently associated with increased
PERSPECTIVES
WHAT’S KNOWN? TR is often observed in patients with LF-LG
AS and low LVEF, but its impact on prognosis is unknown.
WHAT’S NEW? Among patients with LF-LG AS, those with TR
grade $2 have a 2-fold increased risk of mortality. Furthermore,
TR grade $3 is independently associated with increased 30-day
mortality in the subset of patients undergoing AVR.
WHAT’S NEXT? The presence and severity of TR should
be systematically integrated in the risk stratiﬁcation
process of patients with LF-LG AS and reduced LVEF.
Further studies are needed to determine whether
concomitant tricuspid annuloplasty would translate
into better outcomes in the subset of patients
undergoing AVR.
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59530-day mortality in patients undergoing AVR. Hence,
assessment of TR severity should be systematically
integrated in the risk stratiﬁcation and therapeutic
decision making in patients with LF-LG AS and
low LVEF. Further studies are needed to determine
whether TR is a risk marker or risk factor for mortality
and whether surgical correction of TR at the time of
AVR improves outcomes in this high-risk population.
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